Linagliptin/Metformin Sandoz

Linagliptin and Metformin Hydrochloride, the active ingredients in Linagliptin/Metformin Sandoz, are a DPP‑4 inhibitor and a biguanide presented as oral tablets for oral use. They treat type 2 diabetes mellitus in adult patients.

GNH USA supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin/Metformin Sandoz is used in the management of type 2 diabetes, a chronic metabolic disorder characterized by elevated blood glucose.

Type 2 diabetes mellitus: improves glycemic control when diet and exercise are insufficient. Combination therapy with other antidiabetics: provides additional glucose‑lowering effect. Patients inadequately controlled on metformin alone: adds DPP‑4 inhibition to enhance insulin secretion.

Adverse reactions reported with Linagliptin/Metformin Sandoz include both common and rare events.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache - Dizziness - Hypoglycemia (especially when combined with sulfonylureas)

Serious or Rare Side Effects: - Lactic acidosis - Severe allergic reactions (anaphylaxis, angioedema) - Pancreatitis - Hepatic failure - Severe hypoglycemia - Renal impairment

Key safety considerations for Linagliptin/Metformin Sandoz include the following.

Renal function: assess before initiating and monitor regularly. Hepatic function: evaluate for impairment. Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. Elderly patients: use with caution due to increased sensitivity. Severe renal impairment: contraindicated. Store at ambient temperature: keep in original packaging, protect from moisture.

Linagliptin/Metformin Sandoz may interact with several medicines; the interactions are grouped by clinical significance.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin levels. - Cimetidine: can increase metformin plasma concentration. - Iodinated contrast agents: may precipitate renal dysfunction. - Diuretics (loop/thiazide): affect metformin clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: monitor renal function. - NSAIDs: can reduce renal clearance of metformin. - Alcohol: heightens risk of lactic acidosis. - Thyroid hormones: may alter glycemic control.